See the DrugPatentWatch profile for Adbry
What exclusivity does Adbry (tralokinumab) have?
Adbry (tralokinumab) has marketing exclusivity in the U.S. tied to the Food and Drug Administration (FDA) regulatory framework for biologics. Marketing exclusivity is separate from patent protection and can limit when competitors can market an approved “reference” product (or a biosimilar) after an FDA approval pathway is used. The specific exclusivity type and end date depend on the approval history for Adbry and the exclusivity granted by FDA for that approval.
When does Adbry’s marketing exclusivity expire?
To state a precise expiration date, the exact FDA exclusivity record for Adbry’s relevant approval (and any supplements that triggered additional exclusivity or protections) is needed. “Marketing exclusivity” for biologics is not a single universal term; it can vary by whether the product received application-era exclusivity and whether any changes involved exclusivity-extending supplements.
If you share which Adbry indication you mean (or the approval year/label you’re looking at), I can pin down the matching exclusivity end date using the FDA exclusivity listing for that specific approval.
Does exclusivity block biosimilars, or only “new” marketing approvals?
Marketing exclusivity generally restricts the ability of other products to rely on certain FDA submissions for approval timing. It may delay approvals even if a biosimilar product can theoretically be developed under a biosimilar pathway, because FDA marketing exclusivity can prevent approval from landing until the exclusivity period ends. Patent litigation can overlap with this, but marketing exclusivity and patents are enforced differently and can end at different times.
What’s the difference between marketing exclusivity and patents for Adbry?
Marketing exclusivity is an FDA-determined regulatory protection tied to the approval of the original product (and sometimes supplemental approvals). Patents are legal protections that can be enforced through courts, including via FDA-related patent listings and litigation (often determining whether and when a competitor can launch).
So even if marketing exclusivity ends, companies can still face patent barriers; and even if patents expire, FDA marketing exclusivity can still delay approval or launch.
Why are people searching “Adbry exclusivity” alongside biosimilar entry?
Because biosimilar entry timing is driven by both regulatory exclusivity and patent status. Many searches about “exclusivity” come up when stakeholders want to forecast the earliest point when an FDA-approved competing product could market in the U.S.
What you can do next to get the exact exclusivity end date
If you provide any one of the following, the exclusivity calculation becomes specific:
- The FDA approval date you care about (initial approval vs a specific label expansion)
- The Adbry indication (the label section)
- The reference product name used in the exclusivity record (sometimes listings differ by formulation/strength)
- A link or screenshot of the exclusivity listing you’re looking at
Sources (not provided)
No source material was included with your prompt, so I can’t cite a specific FDA exclusivity listing or date.